Drugs / Advair Diskus
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 42 trials | ||||||
| Phase 4 | NCT03219866 | Oct 2017 → Apr 2020 | chronic obstructive pulmonary disease | Wake Forest University Health Sciences | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00974246 | Oct 2009 → Jul 2011 | chronic obstructive pulmonary disease, depressive disorder | Valley Medical Research | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00385463 | Apr 2006 → Apr 2007 | asthma, seasonal allergic rhinitis | Creighton University | Withdrawn | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT02251379 Background | Oct 2014 → Nov 2018 | asthma | Johns Hopkins University | Completed | No outcome recorded |
| Phase 3 | NCT03676413 Comparator | Oct 2018 → Aug 2019 | asthma | Respirent Pharmaceuticals Co Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Advair diskus | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00974246 ↗ |
| Known as | FSC | “Adding Advair Diskus 100/50mcg (FSC) BID and Singulair 10mg is added to placebo Diskus BID” NCT00385463 ↗ |
| Route | Inhaled | “1 inhalation bid” NCT00974246 ↗ |